Drug Adverse Event Reporting During COVID-19 Lockdown

The global COVID-19 pandemic has brought new urgency and challenges to reporting drug adverse events in clinical trials and the consumer market.

"It may well be the case in the months to come that we learn of adverse events which took place during the lockdown but which are only reported at a much later stage," suggests Dr. Thomas Leigh, an Executive Medical Director and Head of the Medical Group within Patient Safety Solutions & Adjudication for Covance.

"The pandemic and its effects are significant, and it will be very important for all of us involved in the assessment of safety of medicines to look out for evidence of safety events which perhaps have not previously come to light."